1502655-48-2 Usage
Uses
Used in Pharmaceutical Industry:
Ledipasvir diacetone is used as an antiviral agent for the treatment of chronic hepatitis C virus (HCV) infections. It targets the NS5A protein, inhibiting the replication of the virus and reducing the viral load in the body.
Used in Combination Therapy:
Ledipasvir diacetone is often used in combination with other antiviral medications to enhance its effectiveness in treating HCV infections. This combined approach helps to achieve higher rates of sustained virologic response and improved liver function in patients with chronic HCV infections.
Clinical Applications:
In clinical trials, Ledipasvir diacetone has demonstrated promising results, showing high rates of sustained virologic response and improved liver function in patients with chronic HCV infections. Its use in combination with other antiviral medications has further increased its therapeutic potential, making it a valuable component in the treatment of hepatitis C.
Check Digit Verification of cas no
The CAS Registry Mumber 1502655-48-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,0,2,6,5 and 5 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1502655-48:
(9*1)+(8*5)+(7*0)+(6*2)+(5*6)+(4*5)+(3*5)+(2*4)+(1*8)=142
142 % 10 = 2
So 1502655-48-2 is a valid CAS Registry Number.
1502655-48-2Relevant articles and documents
SOLID FORMS OF AN ANTIVIRAL COMPOUND
-
Paragraph 0263-0264, (2014/01/07)
Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
SYNTHESIS OF ANTIVIRAL COMPOUND
-
Paragraph 0253; 0254, (2014/01/07)
The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
